Hanyu Medical

Shanghai Hanyu Medical Technology Co., Ltd. (Hanyu Medical) was established at the end of 2016 and is located in Minhang District, Shanghai. With the mission of "Defending Life, Benefiting the World," the company focuses on the research, development, production, and commercialization of interventional devices for structural heart diseases and electrophysiology products. In the field of structural heart disease interventional devices, the company's innovative medical device, the "ValveClamp® Mitral Valve Clip System," officially received approval from the National Medical Products Administration in early September 2023, becoming the first domestically produced mitral regurgitation interventional device approved for marketing in China. The company has a refined and diversified pipeline of products under development in this field: the new atrial septal defect occluder ReAces (Chinese name: Rui Ao) has completed clinical enrollment and is currently in follow-up; the percutaneous mitral valve clip and delivery system ValveClasp entered the special review process for innovative medical devices by the Chinese government in 2023 and is currently undergoing clinical enrollment. The company aims to comprehensively address the unmet clinical needs in China’s structural heart disease field, providing patients with high-quality, cost-effective integrated cardiac disease solutions to improve survival rates, life expectancy, and quality of life.